文献リスト

1）Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012; 56: 1181-8

2）Boonstra K, Kunst AE, Stadhouders PH, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int. 2014; 34: e31-8

3）McNally RJ, James PW, Ducker S, et al. No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England. Am J Epidemiol. 2014; 179: 492-8

4）Qin B, Wang J, Chen J, et al. Association of human leukocyte antigen class II with susceptibility to primary biliary cirrhosis: a systematic review and meta-analysis. PLoS One. 2013; 8: e79580

5）Li YJ, Tang YW, Shi YQ, et al. Polymorphisms in the vitamin D receptor gene and risk of primary biliary cirrhosis: a meta-analysis. J Gastroenterol Hepatol. 2014; 29: 706-15

6）Mo C, Lu Y, Deng Y, et al. Lack of association between vitamin D receptor gene ApaI, BsmI, and TaqI polymorphisms and primary biliary cirrhosis risk: a meta-analysis. Tumour Biol. 2014; 35: 4913-20

7）Joshita S, Umemura T, Nakamura M, et al. STAT4 gene polymorphisms are associated with susceptibility and ANA status in primary biliary cirrhosis. Dis Markers. 2014; 2014: 727393

8）Ohishi Y, Nakamuta M, Ishikawa N, et al. Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol. 2014; 49: 332-42

9）Kohjima M, Enjoji M, Yada R, et al. Pathophysiological analysis of primary biliary cirrhosis focusing on choline/phospholipid metabolism. Liver Int. 2014 Mar 12. [Epub ahead of print]

10）Kar SP, Seldin MF, Chen W, et al. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes Immun. 2013; 14: 179-86

11）Nakamura M, Nishida N, Kawashima M, et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet. 2012; 91: 721-8

12）Aiba Y, Harada K, Komori A, et al. Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis. Liver Int. 2014; 34: 679-88

13）Carbone M, Lleo A, Sandford RN, et al. Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. Eur J Immunol. 2014; 44: 945-54

14）Selmi C, Cavaciocchi F, Lleo A, et al. Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. Front Immunol. 2014; 5: 128

15）Sasaki M, Miyakoshi M, Sato Y, et al. Chemokine-chemokine receptor CCL2-CCR2 and CX3CL1-CX3CR1 axis may play a role in the aggravated inflammation in primary biliary cirrhosis. Dig Dis Sci. 2014; 59: 358-64

16）Sasaki M, Kakuda Y, Miyakoshi M, et al. Infiltration of inflammatory cells expressing mitochondrial proteins around bile ducts and in biliary epithelial layer may be involved in the pathogenesis in primary biliary cirrhosis. J Clin Pathol. 2014; 67: 470-6

17）Sasaki M, Miyakoshi M, Sato Y, et al. Increased expression of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis. Liver Int. 2013; 33: 312-20

18）Harada K, Kakuda Y, Sato Y, et al. Alteration of energy metabolism in the pathogenesis of bile duct lesions in primary biliary cirrhosis. J Clin Pathol. 2014; 67: 396-402

19）Floreani A, Infantolino C, Franceschet I, et al. Pregnancy and Primary Biliary Cirrhosis: A Case-Control Study. Clin Rev Allergy Immunol. 2014 Jul 3. [Epub ahead of print]

20）Efe C, Kahramanoĝlu-Aksoy E, Yilmaz B, et al. Pregnancy in primary biliary cirrhosis. Autoimmun Rev. 2014 May 27. [Epub ahead of print]

21）Trivedi PJ, Kumagi T, Al-Harthy N, et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2014; 12: 1179-85

22）Wendum D, Boëlle PY, Bedossa P, et al. Primary biliary cirrhosis: proposal for a new simple histological scoring system. Liver Int. 2014 Jun 17. [Epub ahead of print]

23）Kobayashi M, Kakuda Y, Harada K, et al. Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis. World J Gastroenterol. 2014; 20: 3597-608

24）Abe K, Takahashi A, Nozawa Y, et al. The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases. Med Mol Morphol. 2014; 47: 162-8

25）Monoe K, Takahashi A, Abe K, et al. Evaluation of nailfold capillaroscopy findings in patients with primary biliary cirrhosis. Hepatol Res. 2014; 44: E129-36

26）Tovoli F, Granito A, Giampaolo L, et al. Nailfold capillaroscopy in primary biliary cirrhosis: a useful tool for the early diagnosis of scleroderma. J Gastrointestin Liver Dis. 2014; 23: 39-43

27）Hu SL, Zhao FR, Hu Q, et al. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One. 2014; 9: e101916

28）Tsuboi H, Ohira H, Asashima H, et al. Anti-M3 muscarinic acetylcholine receptor antibodies in patients with primary biliary cirrhosis. Hepatol Res. 2014 Apr 21. [Epub ahead of print]

29）Mankaï A, Manoubi W, Ghozzi M, et al. High Frequency of Antiphospholipid Antibodies in Primary Biliary Cirrhosis. J Clin Lab Anal. 2014 Mar 28. [Epub ahead of print]

30）Sfakianaki O, Tzardi M, Voumvouraki A, et al. Presence of disease specific autoantibodies against liver sinusoidal cells in primary biliary cirrhosis. World J Hepatol. 2013; 5: 568-76

31）Yamagiwa S, Kamimura H, Takamura M, et al. Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance. World J Gastroenterol. 2014; 20: 2606-12

32）Trivedi PJ, Bruns T, Cheung A, et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol. 2014; 60: 1249-58

33）Rudic JS, Poropat G, Krstic MN, et al. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012; 1: CD009145

34）Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013; 57: 1931-41

35）Cuperus FJ, Halilbasic E, Trauner M. Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol. 2014; 30: 279-86

36）Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2014; 34: 197-203

37）Silveira MG, Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother. 2014; 15: 365-72

38）Flores A, Mayo MJ. Primary biliary cirrhosis in 2014. Curr Opin Gastroenterol. 2014; 30: 245-52

39）Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014; 60: 612-7

40）Umemura T, Katsuyama Y, Yoshizawa K, et al. Human leukocyte antigen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepatitis in Japan. PLoS One. 2014; 9: e100565

41）de Boer YS, van Gerven NM, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type1. Gastroenterology. 2014; 147: 443-52

42）Pischke S, Gisa A, Suneetha PV, et al. Increased HEV seroprevalence in patients with autoimmune hepatitis. PLoS One. 2014; 9: e85330

43）Taubert R, Hardtke-Wolenski M, Noyan F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014; 61: 1106-14

44）Ikeda A, Aoki N, Kido M, et al. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice. Hepatology. 2014; 60: 224-36

45）Xu YT, Liu DJ, Meng FY, et al. Possible benefit of splenectomy in liver transplantation for autoimmune hepatitis. Hepatobiliary Pancreat Dis Int. 2014; 13: 328-31

46）Onji M, Zeniya M, Yamamoto K, et al. Autoimmune hepatitis: Diagnosis and treatment guide Japan, 2013. Hepatol Res. 2014; 44: 368-70

47）Matsumoto K, Miyake Y, Matsushita H, et al. Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 2014; 29: 110-5

48）Kanno Y, Watanabe H, Takahashi A, et al. Anti-phosphoenolpyruvate carboxykinase 2 antibody in patients with autoimmune hepatitis. Hepatol Res. 2014; 44: 1019-25

49）Miyake Y, Yamamoto K, Matsushita H, et al. Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis. Hepatol Res. 2014 Feb 8. [Epub ahead of print]

50）Yamagiwa S, Kamimura H, Takamura M, et al. Presence of antibodies against self human leukocyte antigen class II molecules in autoimmune hepatitis. Int J Med Sci. 2014; 11: 850-6

51）Couto CA, Bittencourt PL, Porta G, et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology. 2014; 59: 592-600

52）Zhang WC, Zhao FR, Chen J, et al. Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis. PLoS One. 2014; 9: e92267

53）Tan L, Zhang Y, Peng W, et al. Detection of anti-lactoferrin antibodies and anti-myeloperoxidase antibodies in autoimmune hepatitis: a retrospective study. J Immunoassay Immunochem. 2014; 35: 388-97

54）Yeoman AD, Westbrook RH, Zen Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcome. J Hepatol. 2014; 61: 876-82

55）Chen J, Eslick GD, Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther. 2014; 39: 117-24

56）Efe C, Kav T, Aydin C, et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. Dig Dis Sci. 2014 Jul 8. [Epub ahead of print]

57）Zhang Y, Lu J, Dai W, et al. Combination therapy of ursodeoxycholic Acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis. Gastroenterol Res Pract. 2013; 2013: 490731

58）Yoshioka Y, Taniai M, Hashimoto E, et al. Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy. Hepatol Res. 2014; 44: 947-55

59）Efe C, Ozaslan E, Heurgué-Berlot A, et al. Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2014; 26: 532-7

60）Ozaslan E, Efe C, Heurgué-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2014; 12: 863-9

61）Deneau M, Book LS, Guthery SL, et al. Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis: a population-based study. J Pediatr. 2014; 164: 714-9

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp